1
|
Zheng W, Yang S, Chen X. The pharmacological and pharmacokinetic properties of obacunone from citrus fruits: A comprehensive narrative review. Fitoterapia 2023; 169:105569. [PMID: 37315716 DOI: 10.1016/j.fitote.2023.105569] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/26/2023] [Revised: 06/06/2023] [Accepted: 06/11/2023] [Indexed: 06/16/2023]
Abstract
Limonoids are a class of oxygenated terpenoids that exist mainly in citrus fruits. As a kind of limonoid, obacunone has attracted more and more researchers' attention because of its extensive pharmacological activities. The purpose of the narrative review is to systematically review relevant studies on the pharmacological effects and pharmacokinetic characteristics of obacunone to provide researchers with the latest and useful information. Pharmacological studies have shown that obacunone has a variety of pharmacological activities, such as anticancer, antioxidant, anti-inflammatory, anti-diabetes, neuroprotection, antibiosis, and antivirus. Among them, the anticancer effect is the most prominent. Pharmacokinetic studies have shown that the oral bioavailability of obacunone is low. This indicates the presence of high first-pass metabolism. We hope that this paper can help relevant scholars understand the progress in pharmacological and pharmacokinetic research of obacunone and help the further development of obacunone as a functional food.
Collapse
Affiliation(s)
- Wenhao Zheng
- Department of Dermatology, Chongqing Hospital of Traditional Chinese Medicine, Chongqing 400011, PR China
| | - Shi Yang
- Cardiovascular Department, Chongqing Hospital of Traditional Chinese Medicine, Chongqing 400011, PR China
| | - Xin Chen
- Department of Dermatology, Chongqing Jiangbei Hospital of Traditional Chinese Medicine, Chongqing 400020, PR China.
| |
Collapse
|
2
|
Zhao J, He J, Xu J. Mechanism-Based Inactivation of Cytochrome P450 3A by Evodol. Xenobiotica 2023:1-11. [PMID: 37092795 DOI: 10.1080/00498254.2023.2207200] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 04/25/2023]
Abstract
1. Evodol is one of the furanoids isolated from the fruits of Evodia rutaecarpa that has been widely prescribed for the treatment of gastrointestinal diseases in China. The aim of this study was to investigate the inhibitory effect of evodol on CYP3A.2. A 30-min preincubation of evodol with human liver microsomes raised an obvious left IC50 shift, 3.9-fold for midazolam 1'-hydroxylation and 3.2-fold for testosterone 6β-hydroxylation. Evodol inactivated CYP3A in a time-, concentration- and NADPH-dependent manner, with KI and kinact of 5.1 μM and 0.028 min-1 for midazolam 1'-hydroxylation and 3.0 μM and 0.022 min-1 for testosterone 6β-hydroxylation.3. Co-incubation of ketoconazole attenuated the inactivation while inclusion of glutathione (GSH) and catalase/superoxide dismutase displayed no such protection.4. cis-Butene-1, 4-dial (BDA) intermediate derived from evodol were trapped by glutathione and N-acetyl-lysine in microsomes and characterized by HR-MS spectra. The BDA intermediate was believed to play a key role in CYP3A inactivation. CYP3A4 and 2C9 were the primary enzymes contributing to the bioactivation of evodol.5. To sum up, for the first time evodol was characterized as a mechanism-based inactivator of CYP3A.
Collapse
Affiliation(s)
- Jie Zhao
- Pharmaceutical Animal Experimental Center, China Pharmaceutical University, Nanjing 210009, China
| | - Jingyu He
- R&D Institute, Chia Tai Tianqing Pharmaceutical Group Co., LTD, Nanjing 211122, China
| | - Jie Xu
- Department of Phase I Clinical Trial Research, Nanjing Gaoxin Hospital, Nanjing 210031, China
| |
Collapse
|
3
|
Quintal Martínez JP, Segura Campos MR. Bioactive compounds and functional foods as coadjuvant therapy for thrombosis. Food Funct 2023; 14:653-674. [PMID: 36601778 DOI: 10.1039/d2fo03171j] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/14/2022]
Abstract
Cardiovascular diseases (CVDs) are the leading cause of death. The most common cardiovascular pathologies are thromboembolic diseases. Antithrombotic therapy prevents thrombus formation or dissolves that previously constituted. However, it presents a high rate of accidents such as gastric bleeding and cerebrovascular embolism. Plant foods and their secondary metabolites have been reported to regulate blood hemostasis. This review article aims to propose plant foods and their metabolites as adjuvant therapy for the management of thromboembolic diseases. Various databases were consulted, using antiplatelet, anticoagulant, and fibrinolytic as key terms. In total, 35 foods and 24 secondary metabolites, via in vitro, in vivo, and clinical studies, have been reported to regulate platelet aggregation, blood coagulation, and fibrinolysis. According to the studies presented in this review, plant foods with effects at concentrations less than 50 μg mL-1 and secondary metabolites with IC50 less than 100 μM can be considered agents with high antithrombotic potential. This review suggests that plant foods and their secondary metabolites should be used to develop foods, ingredients and nutraceuticals with functional properties. The evidence presented in this review shows that plant foods and their bioactive compounds could be used as adjuvants for the treatment and prevention of thrombotic complications. However, further in vivo and clinical trials are required to establish effective and safe doses.
Collapse
|
4
|
Xia H, Dai Y, Zhao C, Zhang H, Shi Y, Lou H. Chromatographic and mass spectrometric technologies for chemical analysis of Euodiae fructus: A review. PHYTOCHEMICAL ANALYSIS : PCA 2023; 34:5-29. [PMID: 36442477 DOI: 10.1002/pca.3187] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 04/01/2022] [Revised: 10/22/2022] [Accepted: 10/27/2022] [Indexed: 06/16/2023]
Abstract
INTRODUCTION Euodiae fructus, also known as Evodiae fructus, is a popular Chinese herbal medicine derived from the dried, nearly ripe fruits of Tetradium ruticarpum (A. Juss.) T. G. Hartley. The main bioactive constituents of Euodiae fructus are alkaloids, limonoids, flavonoids, and anthraquinones. The contents of these compounds vary greatly between different plant species, geographic locations, and harvest times, which thus affect the therapeutic effects. OBJECTIVES We aimed to summarize the chromatographic and mass spectrometric technologies applied for chemical analysis and quality evaluation of Euodiae fructus. Moreover, we aimed to emphasize the diverse soft ionization techniques and mass analyzers of LC-MS methods for assessment of Euodiae fructus. METHODOLOGY A literature study was carried out by retrieving articles published between January 1988 and December 2021 from well-known databases, including PubMed, ASC, Elsevier, ScienceDirect, J·STAGE, Thieme, Taylor & Francis, Springer Link, Wiley Online Library, and CNKI. The chemical analysis methods were described in several categories in accordance with the used analytical techniques, including thin-layer chromatography (TLC), high-performance liquid chromatography (HPLC), high-performance liquid chromatography-mass spectrometry (HPLC-MS), gas chromatography-mass spectrometry (GC-MS), capillary electrophoresis (CE), and counter-current chromatography (CCC). RESULTS This review systematically summarizes the achievements in chemical analysis and quality evaluation of Euodiae fructus published in over three decades, covering the various chromatographic and mass spectrometric technologies applied for identification and quantification of phytochemical constituents. CONCLUSION The summary serves as an important basis for future phytochemical research and implementation of quality control methods in order to ensure the efficacy and safety of Euodiae fructus.
Collapse
Affiliation(s)
- Hongmin Xia
- School of Pharmaceutical Sciences, Shandong University, Jinan, China
- Key Disciplines on Analysis of Traditional Chinese Medicine of SATCM, the Key Unit for Research of Technique and Principle of Honey-Processing and Carbonizing of SATCM, Shandong Key Laboratory of Chinese Medicine Quality Standard Research, Taishan Scholar-Distinguished Experts Position, Shandong Academy of Chinese Medicine, Jinan, China
| | - Yanpeng Dai
- Key Disciplines on Analysis of Traditional Chinese Medicine of SATCM, the Key Unit for Research of Technique and Principle of Honey-Processing and Carbonizing of SATCM, Shandong Key Laboratory of Chinese Medicine Quality Standard Research, Taishan Scholar-Distinguished Experts Position, Shandong Academy of Chinese Medicine, Jinan, China
| | - Chengxin Zhao
- The People's Republic of China Taian Customs, Taian, China
| | - Huimin Zhang
- Key Disciplines on Analysis of Traditional Chinese Medicine of SATCM, the Key Unit for Research of Technique and Principle of Honey-Processing and Carbonizing of SATCM, Shandong Key Laboratory of Chinese Medicine Quality Standard Research, Taishan Scholar-Distinguished Experts Position, Shandong Academy of Chinese Medicine, Jinan, China
| | - Yusheng Shi
- Key Laboratory of Biotechnology and Bioresources Utilization, Educational of Minister, College of Life Science, Dalian Nationalities University, Dalian, China
- National-Local Joint Engineering Research Center for Drug-Research and Development (R&D) of Neurodegenerative Diseases, Dalian Medical University, Dalian, China
- Academy of Integrative Medicine, Dalian Medical University, Dalian, China
| | - Hongxiang Lou
- School of Pharmaceutical Sciences, Shandong University, Jinan, China
| |
Collapse
|
5
|
Wu G, Hao Q, Liu B, Zhou J, Fan C, Liu R. Network pharmacology-based screening of the active ingredients and mechanisms of evodiae fructus anti-glioblastoma multiforme. Medicine (Baltimore) 2022; 101:e30853. [PMID: 36181021 PMCID: PMC9524918 DOI: 10.1097/md.0000000000030853] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/05/2023] Open
Abstract
BACKGROUND Evodiae fructus has been shown to have anti-glioblastoma multiforme (GBM) effects. However, its anti-GBM active components and mechanism remain unclear. In this study, the active components of evodiae fructus were screened by network pharmacology to explore the possible molecular mechanism of resistance to GBM. MATERIALS AND METHODS The main active ingredients of evodiae fructus were derived from Traditional Chinese Medicine Systems Pharmacology Database and Analysis Platform (TCMSP) and Batch-traditional Chinese medicine (TCM). TCMSP and Swiss absorption, distribution, metabolism and elimination (ADME) predict genetic targets for ingredients that meet pharmacological criteria. GBM-related targets were obtained from DisGeNet, GeneCards, Online Mendelian Inheritance in Man (OMIM), Therapeutic Target Database (TTD), and TCGA. A Venn diagram was used to obtain the common targets of evodiae fructus and GBM. Protein-protein interaction (PPI) networks and component-disease target networks were constructed using Cytoscape 3.8.1 software for visualization. GBM gene differential expression was visualized by VolcaNoseR, and potential targets were enriched by Gene Ontology (GO) function and annotated by the Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway by SRplot. Molecular docking verification was conducted using AutoDock Vina software. RESULTS According to the screening conditions, 24 active components and 80 drug targets were obtained. The PPI network contains 80 proteins. The molecular docking verification showed the molecular docking affinity of the core active compounds in evodiae fructus with CASP3, JUN, EGFR, and AKT1. CONCLUSIONS This study preliminarily identified the various molecular targets and multiple pathways of evodiae fructus against GBM.
Collapse
Affiliation(s)
- Gang Wu
- Department of Neurosurgery, Peking University People’s Hospital, China
| | - Qingpei Hao
- Department of Neurosurgery, Peking University People’s Hospital, China
| | - Bo Liu
- Department of Neurosurgery, Peking University People’s Hospital, China
| | - Jingru Zhou
- Department of Neurosurgery, Peking University People’s Hospital, China
| | - Cungang Fan
- Department of Neurosurgery, Peking University People’s Hospital, China
| | - Ruen Liu
- Department of Neurosurgery, Peking University People’s Hospital, China
- *Correspondence: Ruen Liu, Department of Neurosurgery, Peking University People’s Hospital, No.11 Xizhimen South Street, Beijing 100044, China (e-mail: )
| |
Collapse
|
6
|
Huang Z, Xu H, Chen H, Sun B, Huang H, Fan H, Zheng J. Seco-neferine A-F, three new pairs of benzyltetrahydroisoquinoline alkaloid epimers from Plumula Nelumbinis and their activity. Fitoterapia 2021; 153:104994. [PMID: 34273439 DOI: 10.1016/j.fitote.2021.104994] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/08/2021] [Revised: 07/08/2021] [Accepted: 07/11/2021] [Indexed: 01/15/2023]
Abstract
Three new pairs of benzyltetrahydroisoquinoline (BIQ) alkaloid epimers, Seco-neferine A-F (1-6), were isolated from an EtOH extract of Plumula Nelumbinis. The structures of these compounds were identified by a combination of NMR, HR-ESI-MS, circular dichroism, UV spectroscopic analyses and specific rotations. The structure of compounds 1-6 possesses high similarity with neferine, because these three pairs of epimers have the same skeleton as neferine. Compounds 1,2 and 5,6 are open-loop compounds of position 1' and 1 of neferine respectively. The H connects with position 2' N of compounds 1,2 is replaced by methyl, forming the structure of compounds 3,4. Moreover, six compounds were tested for cytotoxicity against MDA-MB-231 breast cancer cell. Compound 6 displayed moderate inhibitory effects on breast cancer with IC50 of 38.96 μM, while compounds 2,3,4 show certain inhibitory effects.
Collapse
Affiliation(s)
- Zhilin Huang
- School of Biomedical and Pharmaceutical Sciences, Guangdong University of Technology, Guangzhou 510006, PR China
| | - Huaishuang Xu
- School of Traditional Chinese Materia Medica, Shenyang Pharmaceutical University, Shenyang 110016, PR China
| | - Honggeng Chen
- School of Biomedical and Pharmaceutical Sciences, Guangdong University of Technology, Guangzhou 510006, PR China
| | - Bohang Sun
- School of Traditional Chinese Materia Medica, Shenyang Pharmaceutical University, Shenyang 110016, PR China
| | - Huarong Huang
- School of Biomedical and Pharmaceutical Sciences, Guangdong University of Technology, Guangzhou 510006, PR China
| | - Hongxia Fan
- School of Biomedical and Pharmaceutical Sciences, Guangdong University of Technology, Guangzhou 510006, PR China
| | - Junxia Zheng
- School of Biomedical and Pharmaceutical Sciences, Guangdong University of Technology, Guangzhou 510006, PR China.
| |
Collapse
|